CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Talimogene Laherparepvecbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02574260
NCT02574260Phase 2Completed
CompareCT.gov

Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma

BioVex Limited·interventional·Posted Oct 12, 2015·Updated Dec 17, 2015

In Brief

A Phase 2 clinical trial evaluating Talimogene Laherparepvec for Melanoma. Completed, enrolled 3 participants.

Detailed Summary

The primary objective of this extension study was to further assess the safety and tolerability of talimogene laherparepvec. Secondary objectives were to assess objective tumor response rate and survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
CollaboratorsCovance

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2015
Enrollment StartAug 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.7 years ago

Interventions

Talimogene Laherparepvecbiological

Administered by intratumoral injection.